相似文献
1
Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease.
Ann Neurol. 2006 Jan;59(1):174-7. doi: 10.1002/ana.20688.
2
Quantification of nicotinic acetylcholine receptors in Parkinson's disease with (123)I-5IA SPECT.
J Neurol Sci. 2007 May 15;256(1-2):52-60. doi: 10.1016/j.jns.2007.02.014. Epub 2007 Mar 23.
3
Nicotinic α4β2 acetylcholine receptors and cognitive function in Parkinson's disease.
Acta Neurol Scand. 2014 Sep;130(3):164-71. doi: 10.1111/ane.12259. Epub 2014 Apr 25.
4
Decrease of nicotinic receptors in the nigrostriatal system in Parkinson's disease.
J Cereb Blood Flow Metab. 2009 Sep;29(9):1601-8. doi: 10.1038/jcbfm.2009.74. Epub 2009 Jun 3.
5
Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[(125)i]-a-85380.
Neuropsychopharmacology. 2004 Jan;29(1):108-16. doi: 10.1038/sj.npp.1300302.
6
Single photon emission computed tomography experience with (S)-5-[(123)I]iodo-3-(2-azetidinylmethoxy)pyridine in the living human brain of smokers and nonsmokers.
Synapse. 2009 Apr;63(4):339-58. doi: 10.1002/syn.20611.
7
Radiosynthesis and preliminary evaluation of 5-[123/125I]iodo-3-(2(S)-azetidinylmethoxy)pyridine: a radioligand for nicotinic acetylcholine receptors.
Nucl Med Biol. 1999 Feb;26(2):175-82. doi: 10.1016/s0969-8051(98)00086-9.
8
5-(123)I-A-85380 binding to the α4β2-nicotinic receptor in mild cognitive impairment.
Neurobiol Aging. 2010 Nov;31(11):1885-93. doi: 10.1016/j.neurobiolaging.2008.10.008. Epub 2008 Nov 25.
9
A spatial covariance I-5IA-85380 SPECT study of α4β2 nicotinic receptors in Alzheimer's disease.
Neurobiol Aging. 2016 Nov;47:83-90. doi: 10.1016/j.neurobiolaging.2016.07.017. Epub 2016 Jul 30.
10
Influence of acetylcholine levels on the binding of a SPECT nicotinic acetylcholine receptor ligand [123I]5-I-A-85380.
Synapse. 2003 Jun 1;48(3):116-22. doi: 10.1002/syn.10194.
引用本文的文献
1
Cortical α4β2-nicotinic acetylcholine receptors and cognitive decline in Parkinson's disease.
J Parkinsons Dis. 2025 Mar;15(2):374-386. doi: 10.1177/1877718X241313373. Epub 2025 Feb 2.
2
Visual hallucinations in Parkinson's disease: spotlight on central cholinergic dysfunction.
Brain. 2025 Feb 3;148(2):376-393. doi: 10.1093/brain/awae289.
3
Patient-specific models link neurotransmitter receptor mechanisms with motor and visuospatial axes of Parkinson's disease.
Nat Commun. 2023 Sep 26;14(1):6009. doi: 10.1038/s41467-023-41677-w.
4
Quantified Striatal Dopaminergic Denervation as Predictor for Motor Outcomes in Parkinson's Disease.
Mov Disord Clin Pract. 2023 Apr 5;10(6):896-902. doi: 10.1002/mdc3.13726. eCollection 2023 Jun.
5
The role of neuroimaging in Parkinson's disease.
J Neurochem. 2021 Nov;159(4):660-689. doi: 10.1111/jnc.15516. Epub 2021 Oct 3.
6
The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain.
Front Aging Neurosci. 2021 Jul 13;13:654931. doi: 10.3389/fnagi.2021.654931. eCollection 2021.
7
Strategies for the Treatment of Parkinson's Disease: Beyond Dopamine.
Front Aging Neurosci. 2020 Jan 31;12:4. doi: 10.3389/fnagi.2020.00004. eCollection 2020.
8
Molecular Imaging of the Cholinergic System in Parkinson's Disease.
Int Rev Neurobiol. 2018;141:211-250. doi: 10.1016/bs.irn.2018.07.027. Epub 2018 Sep 20.
9
Chronic nicotine improves cognitive and social impairment in mice overexpressing wild type α-synuclein.
Neurobiol Dis. 2018 Sep;117:170-180. doi: 10.1016/j.nbd.2018.05.018. Epub 2018 Jun 1.
10
Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
J Neural Transm (Vienna). 2018 Apr;125(4):615-650. doi: 10.1007/s00702-017-1821-9. Epub 2017 Dec 8.
本文引用的文献
1
Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls.
Brain. 2004 Apr;127(Pt 4):791-800. doi: 10.1093/brain/awh088. Epub 2004 Jan 28.
2
Loss of alpha-conotoxinMII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum.
J Neurochem. 2004 Feb;88(3):668-79. doi: 10.1111/j.1471-4159.2004.02177.x.
3
Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET.
Eur J Nucl Med Mol Imaging. 2003 Dec;30(12):1620-9. doi: 10.1007/s00259-003-1320-0. Epub 2003 Oct 2.
4
L-DOPA treatment modulates nicotinic receptors in monkey striatum.
Mol Pharmacol. 2003 Sep;64(3):619-28. doi: 10.1124/mol.64.3.619.
5
Nicotinic receptors in aging and dementia.
J Neurobiol. 2002 Dec;53(4):641-55. doi: 10.1002/neu.10102.
6
Strategies to improve neuroreceptor parameter estimation by linear regression analysis.
J Cereb Blood Flow Metab. 2002 Oct;22(10):1271-81. doi: 10.1097/01.WCB.0000038000.34930.4E.
7
5-Iodo-A-85380 binds to alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) as well as alpha4beta2* subtypes.
J Neurochem. 2002 Apr;81(2):403-6. doi: 10.1046/j.1471-4159.2002.00868.x.
8
Smoking and Parkinson's disease in twins.
Neurology. 2002 Feb 26;58(4):581-8. doi: 10.1212/wnl.58.4.581.
9
Development of ligands for in vivo imaging of cerebral nicotinic receptors.
Behav Brain Res. 2000 Aug;113(1-2):143-57. doi: 10.1016/s0166-4328(00)00209-6.
10
5-Iodo-A-85380, an alpha4beta2 subtype-selective ligand for nicotinic acetylcholine receptors.
Mol Pharmacol. 2000 Mar;57(3):642-9. doi: 10.1124/mol.57.3.642.
Zotero 插件